Document:

Exhibit
10.3

 

Synergy
Strips Corp. 2014

Equity
Incentive Plan

 

1.
ESTABLISHMENT OF PLAN; DEFINITIONS

 

1.1
Purpose. The purpose of the Synergy Strips Corp. 2014 Equity Incentive Plan is to encourage certain officers, employees, directors,
and consultants of Synergy Strips Corp., a Nevada corporation (the “Company”), to acquire and hold stock in the Company as
an added incentive to remain with the Company and increase their efforts in promoting the interests of the Company, and to enable the
Company to attract and retain capable individuals.

 

1.2
Definitions. Unless the context clearly indicates otherwise, the following terms shall have the meanings set forth below:

 

1.2.1
“Award” shall mean, individually or collectively, a grant under this Plan of Stock Options or Stock Awards.

 

1.2.2
“Award Agreement” shall mean a written agreement containing the terms and conditions of an Award, not inconsistent with this
Plan.

 

1.2.3
“Beneficiary” and “Beneficial Ownership” shall mean the person, persons, trust, or trusts that have been designated
by a Grantee in his or her most recent written beneficiary designation filed with the Committee to receive the benefits specified under
this Plan upon such Grantee’s death or to which Awards or other rights are transferred if and to the extent permitted under Section
7.2.4 hereof. If, upon a Grantee’s death, there is no designated Beneficiary or surviving designated Beneficiary, then the term
Beneficiary shall mean the person, persons, trust, or trusts entitled by will or the laws of descent and distribution to receive such
benefits.

 

1.2.4
“Beneficial Owner” shall have the meaning ascribed to such term in Rule 13d-3 under the Exchange Act and any successor to
such Rule.

 

1.2.5
“Board” shall mean the board of directors of the Company.

 

1.2.6
“Change in Control” shall mean a Change in Control as defined in Section 7.1.1(b).

 

1.2.7
“Code” shall mean the Internal Revenue Code of 1986, as it may be amended from time to time.

 

1.2.8
“Committee” shall mean the Board or a committee of the Board appointed pursuant to Section 1.4 of this Plan.

 

1.2.9
“Common Stock” shall mean the Company’s common stock, par value $0.00001 per share.

 

1.2.10
“Company” shall mean Synergy Strips Corp., a Nevada corporation.

 

1.2.11
“Consultants” shall mean individuals who provide services to the Company and any Subsidiary who are not also Employees or
Directors and which services are not in connection with the offer or sale of securities in a capital-raising transaction and do not directly
or indirectly promote or maintain a market for the Company’s securities.

 

1.2.12
“Covered Employee” shall mean a Grantee who, as of the date of vesting and/or payout of an Award, or the date the Company
or any of its Subsidiaries is entitled to a tax deduction as a result of the Award, as applicable, is one of the group of “covered
employees,” as defined in the regulations promulgated under Code Section 162(m), or any successor statute.

 

1.2.13
“Designated Officer” shall mean any executive officer of the Company to whom duties and powers of the Board or Committee
hereunder have been delegated pursuant to Section 1.4.3.

 

    	 

    	 

    

 

1.2.14
“Directors” shall mean those members of the Board or the board of directors of any Subsidiary who are not also Employees.

 

1.2.15
“Disability” shall mean a medically determinable physical or mental condition that causes an Employee, Director, or Consultant
to be unable to engage in any substantial gainful activity and that can be expected to result in death or to be of long-continued and
indefinite duration.

 

1.2.16
“Effective Date” shall mean the effective date of this Plan, which shall be the Stockholder Approval Date.

 

1.2.17
“Employee” shall mean any common law employee, including Officers, of the Company or any Subsidiary as determined under the
Code and the Treasury Regulations thereunder.

 

1.2.18
“Exchange Act” shall mean the Securities Exchange Act of 1934, as amended from time to time, or any successor act thereto.

 

1.2.19
“Fair Market Value” shall mean (i) if the Common Stock is listed on a national securities exchange or the NASDAQ system,
the mean between the highest and lowest sales prices for the Common Stock on such date, or, if no such prices are reported for such day,
then on the next preceding day on which there were reported prices; (ii) if the Common Stock is not listed on a national securities exchange
or the NASDAQ system, the mean between the bid and asked prices for the shares on such date, or if no such prices are reported for such
day, then on the next preceding day on which there were reported prices; or (iii) as determined in good faith by the Board.

 

1.2.20
“Grantee” shall mean an Officer, Employee, Director, or Consultant granted an Award.

 

1.2.21
“Incentive Stock Option” shall mean a Stock Option that meets the requirements of Code Section 422 and is granted pursuant
to the Incentive Stock Option provisions as set forth in Section 2.

 

1.2.22
“Incumbent Board” shall mean the Incumbent Board as defined in Section 7.1.1(b)(ii).

 

1.2.23
“Non-Statutory Stock Option” shall mean a Stock Option that does not meet the requirements of Code Section 422 and is granted
pursuant to the Non-Statutory Stock Option provisions as set forth in Section 3.

 

1.2.24
“Officer” shall mean a person who is an officer of the Company or a Subsidiary within the meaning of Section 16 of the Exchange
Act and the rules and regulations promulgated thereunder.

 

1.2.25
“Performance Award” shall mean an Award under Section 6 hereof.

 

1.2.26
“Performance Measure” shall mean one or more of the following criteria, or such other operating objectives, selected by the
Committee to measure performance of the Company or any Subsidiary for a Performance Period, whether in absolute or relative terms: basic
or diluted earnings per share of Stock; earnings per share of Common Stock growth; revenue; operating income; net income (either before
or after taxes); earnings and/or net income before interest and taxes; earnings and/or net income before interest, taxes, depreciation,
and amortization; return on capital; return on equity; return on assets; net cash provided by operations; free cash flow; Common Stock
price; economic profit; economic value; total stockholder return; and gross margins and costs. Each such measure shall be determined
in accordance with generally accepted accounting principles as consistently applied and, as determined by the independent accountants
of the Company in the case of a Performance Award to a Covered Employee, to the extent intended to meet the performance-based compensation
exception under Code Section 162(m), or as determined by the Committee for other Performance Awards, adjusted to omit the effects of
extraordinary items, gain or loss on the disposal of a business segment, unusual or infrequently occurring events and transactions, and
cumulative effects of changes in accounting principles.

 

1.2.27
“Performance Period” shall mean a period of not less than one (1) year over which the achievement of targets for Performance
Measures is determined.

 

    	 

    	 

    

 

1.2.28
“Person” shall have the meaning ascribed to such term in Section 3(a)(9) of the Exchange Act and used in Sections 13(d) and
14(d) thereof, and shall include a “group” as defined in Section 13(d) thereof.

 

1.2.29
“Plan” shall mean the Synergy Strips Corp. 2014 Equity Incentive Plan as set forth herein and as amended from time to time.

 

1.2.30
“Related Entity” shall mean any Subsidiary, and any business, corporation, partnership, limited liability company, or other
entity designated by the Board, in which the Company or a Subsidiary holds a substantial ownership interest, directly or indirectly.

 

1.2.31
“Restricted Stock” shall mean Common Stock that is issued pursuant to the Restricted Stock provisions as set forth in Section
4.

 

1.2.32
“Restricted Stock Units” shall mean Common Stock that is issued pursuant to the Restricted Stock Unit provisions as set forth
in Section 5.

 

1.2.33
“Rule 16b-3” shall mean Rule 16b-3 promulgated under the Exchange Act or any successor thereto.

 

1.2.34
“Stockholder Approval Date” shall mean the date on which this Plan is approved by the stockholders of the Company eligible
to vote in the election of directors, by a vote sufficient to meet the requirements of Code Sections 162(m) (if applicable) and 422,
Rule 16b-3 under the Exchange Act (if applicable), applicable requirements under the rules of any stock exchange or automated quotation
system on which the Common Stock may be listed on quoted, and other laws, regulations, and obligations of the Company applicable to this
Plan.

 

1.2.35
“Stock Award” shall mean an award of Restricted Stock or Restricted Stock Units granted pursuant to this Plan.

 

1.2.36
“Stock Option” shall mean an option granted pursuant to this Plan to purchase shares of Common Stock.

 

1.2.37
“Subsidiary” shall mean any corporation (other than the Company) in an unbroken chain of corporations beginning with and
including the Company, if each of the corporations other than the last corporation in the unbroken chain owns stock possessing fifty
percent (50%) or more of the total combined voting power of all classes of stock in one of the other corporations in such chain.

 

1.3
Shares of Common Stock Subject to this Plan.

 

1.3.1
Subject to the provisions of Section 7.1, the shares of Common Stock that may be issued pursuant to Stock Options and Stock Awards granted
under this Plan shall not exceed fifteen million five hundred twenty five thousand (15,525,000) shares in the aggregate. If a Stock Option
shall expire and terminate for any reason, in whole or in part, without being exercised or, if Stock Awards are forfeited because the
restrictions with respect to such Stock Awards shall not have been met or have lapsed, the number of shares of Common Stock that are
no longer outstanding as Stock Awards or subject to Stock Options may again become available for the grant of Stock Awards or Stock Options.
There shall be no terms and conditions in a Stock Award or Stock Option that provide that the exercise of an Incentive Stock Option reduces
the number of shares of Common Stock for which an outstanding Non-Statutory Stock Option may be exercised; and there shall be no terms
and conditions in a Stock Award or Stock Option that provide that the exercise of a Non-Statutory Stock Option reduces the number of
shares of Common Stock for which an outstanding Incentive Stock Option may be exercised.

 

1.3.2
The maximum number of shares of Common Stock subject to Awards that may be granted during any one calendar year to any one Covered Employee
shall be limited to five million one hundred seventy five thousand (5,175,000) shares. To the extent required by Code Section 162(m)
and so long as Code Section 162(m) is applicable to persons eligible to participate in this Plan, shares of Common Stock subject to the
foregoing maximum with respect to which the related Award is terminated, surrendered, or cancelled shall nonetheless continue to be taken
into account with respect to such maximum for the calendar year in which granted.

 

    	 

    	 

    

 

1.4
Administration of this Plan.

 

1.4.1
The Plan shall be administered by the Board. In the alternative, the Board may delegate authority to a Committee to administer this Plan
on behalf of the Board, subject to such terms and conditions as the Board may prescribe. Such Committee shall consist of not less than
two (2) members of the Board each of whom is a “non-employee director” within the meaning of Rule 16b-3, or any successor
rule of similar import, and an “outside director” within the meaning of Section 162(m) of the Code and the regulations promulgated
thereunder. Once appointed, the Committee shall continue to serve until otherwise directed by the Board. From time to time, the Board
may increase the size of the Committee and appoint additional members thereof, remove members (with or without cause) and appoint new
members in substitution therefor, fill vacancies, however caused, and remove all members of the Committee and, thereafter, directly administer
this Plan. In the event that the Board is the administrator of this Plan in lieu of a Committee, the term “Committee” as
used herein shall be deemed to mean the Board.

 

1.4.2
The Committee shall meet at such times and places and upon such notice as it may determine. A majority of the Committee shall constitute
a quorum. Any acts by the Committee may be taken at any meeting at which a quorum is present and shall be by majority vote of those members
entitled to vote. Additionally, any acts reduced to writing or approved in writing by all of the members of the Committee shall be valid
acts of the Committee.

 

1.4.3
The Board may, in its sole discretion, divide the duties and powers of the Committee by establishing one or more secondary Committees
to which certain duties and powers of the Board hereunder are delegated (each of which shall be regarded as a “Committee”
under this Plan with respect to such duties and powers), or delegate all of its duties and powers hereunder to a single Committee. Additionally,
if permitted by applicable law, the Board or Committee may delegate any or all of its duties and powers hereunder to a Designated Officer
subject to such conditions and limitations as the Board or Committee shall prescribe. However, only the Committee described under Section
1.4.1 may designate and grant Awards to Grantees who are subject to Section 16 of the Exchange Act or Section 162(m) of the Code. The
Committee shall also have the power to establish sub-plans (which may be included as appendices to this Plan or the respective Award
Agreement), which may constitute separate programs, for the purpose of establishing programs that meet any special tax or regulatory
requirements of jurisdictions other than the United States and its subdivisions. Any such interpretations, rules, administration and
sub-plans shall be consistent with the basic purposes of this Plan.

 

1.4.4
Powers of the Committee. The Committee shall have all the powers vested in it by the terms of this Plan, such powers to include
authority, in its sole and absolute discretion, to grant Awards under this Plan, prescribe Award Agreements and establish programs for
granting Awards. The Committee shall have full power and authority to take all other actions necessary to carry out the purpose and intent
of this Plan, including, but not limited to, the authority to:

(a)
determine the Grantees to whom, and the time or times at which, Awards shall be granted;

 

(b)
determine the types of Awards to be granted;

 

(c)
determine the number of shares of Common Stock and/or amount of cash to be covered by or used for reference purposes for each Award;

 

(d)
impose such terms, limitations, vesting schedules, restrictions, and conditions upon any such Award as the Committee shall deem appropriate,
including without limitation establishing, in its discretion, Performance Measures that must be satisfied before an Award vests and/or
becomes payable, the term during which an Award is exercisable, the purchase price, if any, under an Award, and the period, if any, following
a Grantee’s termination of employment or service with the Company or any Subsidiary during which the Award shall remain exercisable;

 

    	 

    	 

    

 

(e)
modify, extend, or renew outstanding Awards, accept the surrender of outstanding Awards, and substitute new Awards, provided that no
such action shall be taken with respect to any outstanding Award that would materially and adversely affect the Grantee without the Grantee’s
consent, or constitute a repricing of stock options without the consent of the holders of the Company’s voting securities under
Section 1.4.4(f) below;

 

(f)
only with the approval of the holders of the voting securities of the Company to the extent that such approval is required by applicable
law, regulation, or the rules of a national securities exchange or automated quotation system to which the Company is subject, reprice
Incentive Stock Options and Non-Statutory Stock Options either by amendment to lower the exercise price or by accepting such stock options
for cancellation and issuing replacement stock options with a lower exercise price or through any other mechanism;

 

(g)
accelerate the time in which an Award may be exercised or in which an Award becomes payable and waive or accelerate the lapse, in whole
or in part, of any restriction or condition with respect to an Award;

 

(h)
establish objectives and conditions, including targets for Performance Measures, if any, for earning Awards and determining whether Awards
will be paid after the end of a Performance Period; and

 

(i)
permit the deferral of, or require a Grantee to defer such Grantee’s receipt of or the delivery of Stock and/or cash under an Award
that would otherwise be due to such Grantee and establish rules and procedures for such payment deferrals, provided the requirements
of Code Section 409A are met with respect to any such deferral.

 

The
Committee shall have full power and authority to administer and interpret this Plan and to adopt such rules, regulations, agreements,
guidelines, and instruments for the administration of this Plan as the Committee deems necessary, desirable or appropriate in accordance
with the bylaws of the Company.

 

1.4.5
To the maximum extent permitted by law, no member of the Board or Committee or a Designated Officer shall be liable for any action taken
or decision made in good faith relating to this Plan or any Award thereunder.

 

1.4.6
The members of the Board and Committee and any Designated Officer shall be indemnified by the Company in respect of all their activities
under this Plan in accordance with the procedures and terms and conditions set forth in the Certificate of Incorporation and bylaws of
the Company as in effect from time to time. The foregoing right of indemnification shall not be exclusive of any other rights of indemnification
to which such persons may be entitled under the Company’s Certificate of Incorporation and bylaws, as a matter of law, or otherwise.

 

1.4.7
All actions taken and decisions and determinations made by the Committee or a Designated Officer on all matters relating to this Plan
pursuant to the powers vested in it hereunder shall be in the Committee’s or Designated Officer’s sole and absolute discretion
and shall be conclusive and binding on all parties concerned, including the Company, its stockholders, any Grantees, and any other Employee,
and their respective successors in interest.

 

1.5
Amendment or Termination.

 

1.5.1
The Committee, without further approval of the Company’s stockholders, may amend or terminate this Plan or any portion thereof
at any time, except that no amendment shall become effective without prior approval of the stockholders of the Company to increase the
number of shares of Common Stock subject to this Plan or if stockholder approval is necessary to comply with any tax or regulatory requirement
or rule of any national securities exchange or national automated quotation system upon which the Common Stock is listed or quoted (including
for this purpose stockholder approval that is required for continued compliance with Rule 16b-3 or stockholder approval that is required
to enable the Committee to grant Incentive Stock Options pursuant to this Plan).

 

1.5.2
The Committee shall be authorized to make minor or administrative amendments to this Plan as well as amendments to this Plan that may
be dictated by the requirements of U.S. federal or state laws applicable to the Company or that may be authorized or made desirable by
such laws. The Committee may amend any outstanding Award in any manner as provided in Section 1.4.4 and to the extent that the Committee
would have had the authority to make such Award as so amended.

 

    	 

    	 

    

 

 

1.5.3
No amendment to this Plan or any Award may be made that would materially adversely affect any outstanding Award previously made under
this Plan without the approval of the Grantee. Further, no amendment to this Plan or an Award shall be made that would cause any Award
to fail to either comply with or meet an exception from Code Section 409A.

 

1.6
Effective Date and Duration of this Plan. This Plan shall become effective on the Effective Date. This Plan shall terminate at
such time as may be determined by the Board, and no Stock Award or Stock Option may be issued or granted under this Plan thereafter,
but such termination shall not affect any Stock Award or Stock Option theretofore issued or granted.

 

2.
INCENTIVE STOCK OPTION PROVISIONS

 

2.1
Granting of Incentive Stock Options.

 

2.1.1
Only Employees of the Company shall be eligible to receive Incentive Stock Options under this Plan. Officers, Directors, and Consultants
of the Company who are not also Employees shall not be eligible to receive Incentive Stock Options.

 

2.1.2
The purchase price of each share of Common Stock subject to an Incentive Stock Option shall not be less than 100% of the Fair Market
Value of a share of the Common Stock on the date the Incentive Stock Option is granted. If an Employee owns or is deemed to own (by reason
of the attribution rules applicable under Section 424(d) of the Code) more than 10% of the combined voting power of all classes of stock
of the Company (or any parent corporation or subsidiary corporation of the Company, as those terms are defined in Sections 424(e) and
(f) of the Code, respectively) and an Incentive Stock Option is granted to such Employee, the exercise price of such Incentive Stock
Option (to the extent required by the Code at the time of grant) shall be no less than 110% of the Fair Market Value of a Share on the
date such Incentive Stock Option is granted.

 

2.1.3
No Incentive Stock Option shall be exercisable more than ten (10) years from the date the Incentive Stock Option was granted; provided
however, that if a Grantee owns or is deemed to own (by reason of the attribution rules of Section 424(d) of the Code) more than 10%
of the combined voting power of all classes of stock of the Company (or any parent corporation or subsidiary corporation of the Company,
as those terms are defined in Sections 424(e) and (f) of the Code, respectively) and the Incentive Stock Option is granted to such Grantee,
the term of the Incentive Stock Option shall be (to the extent required by the Code at the time of the grant) for no more than five (5)
years from the date of grant.

 

2.1.4
The Committee shall determine and designate from time to time those Employees who are to be granted Incentive Stock Options and specify
the number of shares subject to each Incentive Stock Option.

 

2.1.5
The Committee, in its sole discretion, shall determine whether any particular Incentive Stock Option shall become exercisable in one
or more installments, specify the installment dates, and, within the limitations herein provided, determine the total period during which
the Incentive Stock Option is exercisable. Further, the Committee may make such other provisions as may appear generally acceptable or
desirable to the Committee or necessary to qualify its grants under the provisions of Section 422 of the Code.

 

2.1.6
The Committee may grant at any time new Incentive Stock Options to an Employee who has previously received Incentive Stock Options or
other options whether such prior Incentive Stock Options or other options are still outstanding, have previously been exercised in whole
or in part, or are cancelled in connection with the issuance of new Incentive Stock Options. The purchase price of the new Incentive
Stock Options may be established by the Committee without regard to the existing Incentive Stock Options or other options.

 

    	 

    	 

    

 

2.1.7
Notwithstanding any other provisions hereof, the aggregate Fair Market Value (determined at the time the option is granted) of the Common
Stock with respect to which Incentive Stock Options are exercisable for the first time by the Employee during any calendar year (under
all such plans of the Grantee’s employer corporation and its parent corporation or subsidiary corporation as those terms are defined
in Sections 424(e) and (f) of the Code, respectively) shall not (to the extent required by the Code at the time of the grant) exceed
One Hundred Thousand Dollars ($100,000). To the extent that such aggregate Fair Market Value shall exceed One Hundred Thousand Dollars
($100,000), or other applicable amount, such Stock Options to the extent of the Common Stock in excess of such limit shall be treated
as Non-Statutory Stock Options. In such case, the Company may designate the shares of Common Stock that are to be treated as Stock acquired
pursuant to the exercise of an Incentive Stock Option.

 

2.2
Exercise of Incentive Stock Options. The exercise price of an Incentive Stock Option shall be payable on exercise of the option
(i) in cash or by check, bank draft, or postal or express money order, (ii) ) if provided in the written Award Agreement and permitted
by applicable law, by the surrender of Common Stock then owned by the Grantee, which Common Stock such Grantee has held for at least
six (6) months, (iii) the proceeds of a loan from an independent broker-dealer whereby the loan is secured by the option or the stock
to be received upon exercise, or (iv) any combination of the foregoing; provided, that each such method and time for payment and
each such borrowing and terms and conditions of repayment shall then be permitted by and be in compliance with applicable law. Shares
of Common Stock so surrendered in accordance with clause (ii) or (iv) shall be valued at the Fair Market Value thereof on the date of
exercise, surrender of such Common Stock to be evidenced by delivery of the certificate(s) representing such shares in such manner, and
endorsed in such form, or accompanied by stock powers endorsed in such form, as the Committee may determine.

 

2.3
Termination of Employment.

 

2.3.1
If a Grantee’s employment with the Company is terminated other than by Disability or death, the terms of any then outstanding Incentive
Stock Option held by the Grantee shall extend for a period ending on the earlier of the date on which such Stock Option would otherwise
expire or three (3) months after such termination of employment, and such Stock Option shall be exercisable to the extent it was exercisable
as of such last date of employment.

 

2.3.2
If a Grantee’s employment with the Company is terminated by reason of Disability, the term of any then outstanding Incentive Stock
Option held by the Grantee shall extend for a period ending on the earlier of the date on which such Stock Option would otherwise expire
or twelve (12) months after such termination of employment, and such Stock Option shall be exercisable to the extent it was exercisable
as of such last date of employment.

 

2.3.3
If a Grantee’s employment with the Company is terminated by reason of death, the representative of his estate or beneficiaries
thereof to whom the Stock Option has been transferred shall have the right during the period ending on the earlier of the date on which
such Stock Option would otherwise expire or twelve (12) months after such date of death, to exercise any then outstanding Incentive Stock
Options in whole or in part. If a Grantee dies without having fully exercised any then outstanding Incentive Stock Options, the representative
of his estate or beneficiaries thereof to whom the Stock Option has been transferred shall have the right to exercise such Stock Options
in whole or in part.

 

3.
NON-STATUTORY STOCK OPTION PROVISIONS

 

3.1
Granting of Stock Options.

 

3.1.1
Officers, Employees, Directors, and Consultants shall be eligible to receive Non-Statutory Stock Options under this Plan.

 

3.1.2
The Committee shall determine and designate from time to time those Officers, Employees, Directors, and Consultants who are to be granted
Non-Statutory Stock Options and the amount subject to each Non-Statutory Stock Option.

 

3.1.3
The Committee may grant at any time new Non-Statutory Stock Options to an Employee, Director, or Consultant who has previously received
Non-Statutory Stock Options or other Stock Options, whether such prior Non-Statutory Stock Options or other Stock Options are still outstanding,
have previously been exercised in whole or in part, or are cancelled in connection with the issuance of new Non-Statutory Stock Options.

 

    	 

    	 

    

 

3.1.4
The Committee shall determine the purchase price of each share of Common Stock subject to a Non-Statutory Stock Option. Such price shall
not be less than 100% of the Fair Market Value of such Common Stock on the date the Non-Statutory Stock Option is granted.

 

3.1.5
The Committee, in its sole discretion, shall determine whether any particular Non-Statutory Stock Option shall become exercisable in
one or more installments, specify the installment dates, and, within the limitations herein provided, determine the total period during
which the Non-Statutory Stock Option is exercisable. Further, the Committee may make such other provisions as may appear generally acceptable
or desirable to the Committee, including the extension of a Non-Statutory Stock Option, provided that such extension does not extend
the option beyond the period specified in Section 3.1.6 below.

 

3.1.6
No Non-Statutory Stock Option shall be exercisable more than ten (10) years from the date such option is granted.

 

3.2
Exercise of Stock Options. The exercise price of a Non-Statutory Stock Option shall be payable on exercise of the Stock Option
(i) in cash or by check, bank draft, or postal or express money order, (ii) if provided in the written Award Agreement and permitted
by applicable law, by the surrender of Common Stock then owned by the Grantee, which Common Stock such Grantee has held for at least
six (6) months, (iii) the proceeds of a loan from an independent broker-dealer whereby the loan is secured by the option or the stock
to be received upon exercise, or (iv) any combination of the foregoing; provided, that each such method and time for payment
and each such borrowing and terms and conditions of repayment shall then be permitted by and be in compliance with applicable law. Shares
of Common Stock so surrendered in accordance with clause (ii) or (iv) shall be valued at the Fair Market Value thereof on the date of
exercise, surrender of such Common Stock to be evidenced by delivery of the certificate(s) representing such shares in such manner, and
endorsed in such form, or accompanied by stock powers endorsed in such form, as the Committee may determine.

 

3.3
Termination of Relationship.

 

3.3.1
If a Grantee’s employment with the Company is terminated, a Director Grantee ceases to be a Director, or a Consultant Grantee ceases
to be a Consultant, other than by reason of Disability or death, the terms of any then outstanding Non-Statutory Stock Option held by
the Grantee shall extend for a period ending on the earlier of the date established by the Committee at the time of grant or three (3)
months after the Grantee’s last date of employment or cessation of being a Director or Consultant, and such Stock Option shall
be exercisable to the extent it was exercisable as of the date of termination of employment or cessation of being a Director or Consultant.

 

3.3.2
If a Grantee’s employment is terminated by reason of Disability, a Director Grantee ceases to be a Director by reason of Disability
or a Consultant Grantee ceases to be a Consultant by reason of Disability, the term of any then outstanding Non-Statutory Stock Option
held by the Grantee shall extend for a period ending on the earlier of the date on which such Stock Option would otherwise expire or
twelve (12) months after the Grantee’s last date of employment or cessation of being a Director or Consultant, and such Stock Option
shall be exercisable to the extent it was exercisable as of such last date of employment or cessation of being a Director or Consultant.

 

3.3.3
If a Grantee’s employment is terminated by reason of death, a Director Grantee ceases to be a Director by reason of death or a
Consultant Grantee ceases to be a Consultant by reason of death, the representative of his estate or beneficiaries thereof to whom the
Stock Option has been transferred shall have the right during the period ending on the earlier of the date on which such Stock Option
would otherwise expire or twelve (12) months following his death to exercise any then outstanding Non-Statutory Stock Options in whole
or in part. If a Grantee dies without having fully exercised any then outstanding Non-Statutory Stock Options, the representative of
his estate or beneficiaries thereof to whom the Stock Option has been transferred shall have the right to exercise such Stock Options
in whole or in part.

 

    	 

    	 

    

 

4.
RESTRICTED STOCK AWARDS

 

4.1
Grant of Restricted Stock.

 

4.1.1
Officers, Employees, Directors and Consultants shall be eligible to receive grants of Restricted Stock under this Plan.

 

4.1.2
The Committee shall determine and designate from time to time those Officers, Employees, Directors and Consultants who are to be granted
Restricted Stock and the number of shares of Common Stock subject to such Stock Award.

 

4.1.3
The Committee, in its sole discretion, shall make such terms and conditions applicable to the grant of Restricted Stock as may appear
generally acceptable or desirable to the Committee.

 

4.2
Termination of Relationship.

 

4.2.1
If a Grantee’s employment with the Company is terminated, a Director Grantee ceases to be a Director, or a Consultant Grantee ceases
to be a Consultant, prior to the lapse of any restrictions applicable to the Restricted Stock, then such Common Stock shall be forfeited
and the Grantee shall return the certificates representing such Common Stock to the Company.

 

4.2.2
If the restrictions applicable to a grant of Restricted Stock shall lapse, then the Grantee shall hold such Common Stock free and clear
of all such restrictions except as otherwise provided in this Plan.

 

5.
RESTRICTED STOCK UNIT AWARDS

 

5.1
Grant of Restricted Stock Units.

 

5.1.1
Officers, Employees, Directors, and Consultants shall be eligible to receive grants of Restricted Stock Units under this Plan.

 

5.1.2
The Committee shall determine and designate from time to time those Officers, Employees, Directors and Consultants who are to be granted
Restricted Stock Units and number of shares of Common Stock subject to such Stock Award.

 

5.1.3
The Committee, in its sole discretion, shall make such terms and conditions applicable to the grant of Restricted Stock Units as may
appear generally acceptable or desirable to the Committee.

 

5.2
Termination of Relationship.

 

5.2.1
If a Grantee’s employment with the Company is terminated, a Director Grantee ceases to be a Director, or a Consultant Grantee ceases
to be a Consultant, prior to the lapse of any restrictions applicable to the Restricted Stock Units, then such Common Stock shall be
forfeited and the Grantee shall return the certificates representing such Common Stock to the Company.

 

5.2.2
If the restrictions applicable to a grant of Restricted Stock Units shall lapse, then the Grantee shall hold such Common Stock free and
clear of all such restrictions except as otherwise provided in this Plan.

 

6.
PERFORMANCE AWARDS

 

6.1
The Committee, in its discretion, may establish targets for Performance Measures for selected Grantees and authorize the granting, vesting,
payment, and/or delivery of Performance Awards in the form of Incentive Stock Options, Non-Statutory Stock Options, Restricted Stock,
and Restricted Stock Units to such Grantees upon achievement of such targets for Performance Measures during a Performance Period. The
Committee, in its discretion, shall determine the Grantees eligible for Performance Awards, the targets for Performance Measures to be
achieved during each Performance Period, and the type, amount, and terms and conditions of any Performance Awards. Performance Awards
may be granted either alone or in addition to other Awards made under this Plan.

 

    	 

    	 

    

 

6.2
After the Company is subject to Code Section 162(m), in connection with any Performance Awards granted to a Covered Employee that are
intended to meet the performance-based compensation exception under Code Section 162(m), the Committee shall (i) establish in the applicable
Award Agreement the specific targets relative to the Performance Measures that must be attained before the respective Performance Award
is granted, vests, or is otherwise paid or delivered, (ii) provide in the applicable Award Agreement the method for computing the portion
of the Performance Award that shall be granted, vested, paid, and/or delivered if the target or targets are attained in full or part,
and (iii) at the end of the relevant Performance Period, and prior to any such grant, vesting, payment, or delivery, certify the extent
to which the applicable target or targets were achieved and whether any other material terms were in fact satisfied. The specific targets
and the method for computing the portion of such Performance Award that shall be granted, vested, paid, or delivered to any Covered Employee
shall be established by the Committee prior to the earlier to occur of (A) ninety (90) days after the commencement of the Performance
Period to which the Performance Measure applies and (B) the elapse of twenty-five percent (25%) of the Performance Period and in any
event while the outcome is substantially uncertain. In interpreting Plan provisions applicable to Performance Measures and Performance
Awards that are intended to meet the performance-based compensation exception under Code Section 162(m), it is the intent of this Plan
to conform with the standards of Section 162(m) of the Code and Treasury Regulations Section 1.162-27(e)(2), and the Committee in interpreting
this Plan shall be guided by such provisions.

 

7.
GENERAL PROVISIONS

 

7.1
Adjustment Provisions.

 

7.1.1
Change of Control.

 

(a)
Effect of “Change in Control.” If and only to the extent provided in the Award Agreement, or to the extent otherwise
determined by the Committee, upon the occurrence of a “Change in Control,” as defined in Section 7.1.1(b):

 

(i)
The Committee shall take such action as it deems appropriate and equitable to effectuate the purposes of this Plan and to protect the
grantees of Awards, which action may include, without limitation, any one or more of the following, provided such action is in compliance
with Code Section 409A if applicable: (i) acceleration or change of the exercise and/or expiration dates of any Award to require that
exercise be made, if at all, prior to the Change in Control; and (ii) cancellation of any Award upon payment to the holder in cash of
the Fair Market Value of the Stock subject to such Award as of the date of (and, to the extent applicable, as established for purposes
of) the Change in Control, less the aggregate exercise price, if any, of the Award.

 

(ii)
Notwithstanding the foregoing or any provision in any Award Agreement to the contrary, if in the event of a Change in Control, the successor
company assumes or substitutes for a Stock Option or Stock Award, then each such outstanding Stock Option or Stock Award shall not be
accelerated as described in Sections 7.1.1(a)(i). For the purposes of this Section 7.1.1(a)(ii), such Stock Option or Stock Award shall
be considered assumed or substituted for if following the Change in Control the Award confers the right to purchase or receive, for each
share of Common Stock subject to the Stock Option or Stock Award immediately prior to the Change in Control, the consideration (whether
stock, cash, or other securities or property) received in the transaction constituting a Change in Control by holders of Common Stock
shares for each Common Stock share held on the effective date of such transaction (and if holders were offered a choice of consideration,
the type of consideration chosen by the holders of a majority of the outstanding shares); provided, however, that if such consideration
received in the transaction constituting a Change in Control is not solely common stock of the successor company or its parent or subsidiary,
the Committee may, with the consent of the successor company or its parent or subsidiary, provide that the consideration to be received
upon the exercise or vesting of a Stock Option or Stock Award, for each Common Stock share subject thereto, will be solely common stock
of the successor company or its parent or subsidiary substantially equal in fair market value to the per share consideration received
by holders of Common Stock shares in the transaction constituting a Change in Control. The determination of such substantial equality
of value of consideration shall be made by the Committee in its sole discretion and its determination shall be conclusive and binding.

 

    	 

    	 

    

 

(b)
Definition of “Change in Control”. Unless otherwise specified in an Award Agreement, a “Change in Control”
shall mean the occurrence of any of the following:

 

(i)
The acquisition by any Person of Beneficial Ownership (within the meaning of Rule 13d-3 promulgated under the Exchange Act) of more than
fifty percent (50%) of either (A) the value of then outstanding equity securities of the Company (the “Outstanding Company Stock”)
or (B) the combined voting power of the then outstanding voting securities of the Company entitled to vote generally in the election
of directors (the “Outstanding Company Voting Securities”) (the foregoing Beneficial Ownership hereinafter being referred
to as a “Controlling Interest”); provided, however, that for purposes of this Section 7.1.1, the following acquisitions shall
not constitute or result in a Change in Control: (v) any acquisition directly from the Company; (w) any acquisition by the Company; (x)
any acquisition by any Person that as of the Effective Date owns Beneficial Ownership of a Controlling Interest; (y) any acquisition
by any employee benefit plan (or related trust) sponsored or maintained by the Company or any Related Entity; or (z) any acquisition
by any entity pursuant to a transaction that complies with clauses (A), (B), and (C) of subsection 7.1.1(b)(iii) below; or

 

(ii)
During any period of two (2) consecutive years (not including any period prior to the Effective Date) individuals who constitute the
Board on the Effective Date (the “Incumbent Board”) cease for any reason to constitute at least a majority of the Board;
provided, however, that any individual becoming a director subsequent to the Effective Date whose election, or nomination for election
by the Company’s stockholders, was approved by a vote of at least a majority of the directors then comprising the Incumbent Board
shall be considered as though such individual were a member of the Incumbent Board, but excluding, for this purpose, any such individual
whose initial assumption of office occurs as a result of an actual or threatened election contest with respect to the election or removal
of directors or other actual or threatened solicitation of proxies or consents by or on behalf of a Person other than the Board; or

 

(iii)
Consummation of a reorganization, merger, statutory share exchange, or consolidation or similar transaction involving the Company or
any of its Related Entities, a sale or other disposition of all or substantially all of the assets of the Company, or the acquisition
of assets or equity of another entity by the Company or any of its Related Entities (each a “Business Combination”), in each
case, unless, following such Business Combination, (A) all or substantially all of the individuals and entities who were the Beneficial
Owners, respectively, of the Outstanding Company Stock and Outstanding Company Voting Securities immediately prior to such Business Combination
beneficially own, directly or indirectly, more than fifty percent (50%) of the value of the then outstanding equity securities and the
combined voting power of the then outstanding voting securities entitled to vote generally in the election of members of the board of
directors (or comparable governing body of an entity that does not have such a board), as the case may be, of the entity resulting from
such Business Combination (including, without limitation, an entity that as a result of such transaction owns the Company or all or substantially
all of the Company’s assets either directly or through one or more subsidiaries) in substantially the same proportions as their
ownership, immediately prior to such Business Combination of the Outstanding Company Stock and Outstanding Company Voting Securities,
as the case may be, (B) no Person (excluding any employee benefit plan (or related trust) of the Company or such entity resulting from
such Business Combination or any Person that as of the Effective Date owns Beneficial Ownership of a Controlling Interest) beneficially
owns, directly or indirectly, fifty percent (50%) or more of the value of the then outstanding equity securities of the entity resulting
from such Business Combination or the combined voting power of the then outstanding voting securities of such entity except to the extent
that such ownership existed prior to the Business Combination, and (C) at least a majority of the members of the Board or other governing
body of the entity resulting from such Business Combination were members of the Incumbent Board at the time of the execution of the initial
agreement, or of the action of the Board, providing for such Business Combination; or

 

(iv)
Approval by the stockholders of the Company of a complete liquidation or dissolution of the Company.

 

7.1.2
Adjustments to Awards. In the event that any extraordinary dividend or other distribution (whether in the form of cash, Common
Stock, or other property), recapitalization, forward or reverse split, reorganization, merger, consolidation, spin-off, combination,
repurchase, share exchange, liquidation, dissolution or other similar corporate transaction or event affects the Common Stock and/or
such other securities of the Company or any other issuer such that a substitution, exchange, or adjustment is determined by the Committee
to be appropriate, then the Committee shall, in such manner as it may deem equitable, substitute, exchange, or adjust any or all of (A)
the number and kind of Shares that may be delivered in connection with Awards granted thereafter, (B) the number and kind of Shares by
which annual per-person Award limitations are measured under this Plan’s provisions, (C) the number and kind of Shares subject
to or deliverable in respect of outstanding Awards, (D) the exercise price, grant price or purchase price relating to any Award and/or
make provision for payment of cash or other property in respect of any outstanding Award, and (E) any other aspect of any Award that
the Committee determines to be appropriate.

 

    	 

    	 

    

 

7.1.3
Adjustments in Case of Certain Transactions. In the event of any merger, consolidation or other reorganization in which the Company
does not survive, or in the event of any Change in Control, any outstanding Awards may be dealt with in accordance with any of the following
approaches, as determined by the agreement effectuating the transaction or, if and to the extent not so determined, as determined by
the Committee: (a) the continuation of the outstanding Awards by the Company, if the Company is a surviving entity, (b) the assumption
or substitution for, as those terms are defined in Section 7.1.1(b)(iv), the outstanding Awards by the surviving entity or its parent
or subsidiary, (c) full exercisability or vesting and accelerated expiration of the outstanding Awards, or (d) settlement of the value
of the outstanding Awards in cash or cash equivalents or other property followed by cancellation of such Awards (which value, in the
case of Stock Options, shall be measured by the amount, if any, by which the Fair Market Value of a share of Common Stock exceeds the
exercise or grant price of the Stock Option as of the effective date of the transaction). The Committee shall give written notice of
any proposed transaction referred to in this Section 7.1.3 a reasonable period of time prior to the closing date for such transaction
(which notice may be given either before or after the approval of such transaction), in order that Grantees may have a reasonable period
of time prior to the closing date of such transaction within which to exercise any Awards that are then exercisable (including any Awards
that may become exercisable upon the closing date of such transaction). A Grantee may condition his exercise of any Awards upon the consummation
of the transaction.

 

7.1.4
Other Adjustments. The Committee (and the Board if and only to the extent such authority is not required to be exercised by the
Committee to comply with Section 162(m) of the Code) is authorized to make adjustments in the terms and conditions of, and the criteria
included in, Awards (including Performance Awards, or performance goals relating thereto) in recognition of unusual or nonrecurring events
(including, without limitation, acquisitions and dispositions of businesses and assets) affecting the Company, any Related Entity or
any business unit, or the financial statements of the Company or any Related Entity, or in response to changes in applicable laws, regulations,
accounting principles, tax rates and regulations or business conditions or in view of the Committee’s assessment of the business
strategy of the Company, any Related Entity or business unit thereof, performance of comparable organizations, economic and business
conditions, personal performance of a Grantee, and any other circumstances deemed relevant; provided that no such adjustment shall be
authorized or made if and to the extent that such authority or the making of such adjustment would cause Stock Options or Stock Awards
granted pursuant to Section 6 to Grantees designated by the Committee as Covered Employees and intended to qualify as “performance-based
compensation” under Code Section 162(m) and the regulations thereunder to otherwise fail to qualify as “performance-based
compensation” under Code Section 162(m) and regulations thereunder.

 

7.1.5
Fractional Shares. No adjustment or substitution provided for in this Section 7.1 shall require the Company to sell a fractional
share, and the total substitution or adjustment with respect to each outstanding Stock Option shall be limited accordingly.

 

7.1.6
Adjustment Certificates. Upon any adjustment made pursuant to this Section 7.1 the Company will, upon request, deliver to the
Grantee a certificate setting forth the exercise price thereafter in effect and the number and kind of shares or other securities thereafter
purchasable on the exercise of such Stock Option.

 

7.2
General.

 

7.2.1
Each Stock Option and Stock Award shall be evidenced by an Award Agreement containing such terms and conditions, not inconsistent with
this Plan, as the Committee shall approve.

 

7.2.2
The granting of a Stock Option or Stock Award in any year shall not give the Grantee any right to similar grants in future years or any
right to be retained in the employ of the Company, and all Employees shall remain subject to discharge to the same extent as if this
Plan were not in effect.

 

7.2.3
No Officer, Employee, Director, or Consultant and no beneficiary or other person claiming under or through him, shall have any right,
title or interest by reason of any Stock Option or any Stock Award to any particular assets of the Company, or any shares of Common Stock
allocated or reserved for the purposes of this Plan or subject to any Stock Option or any Stock Award except as set forth herein. The
Company shall not be required to establish any fund or make any other segregation of assets to assure the payment of any Stock Option
or Stock Award.

 

    	 

    	 

    

 

7.2.4
Limits on Transferability.

 

(a)
Except to the extent otherwise provided in the respective Award Agreement, no Award, other right, or interest granted under this Plan
shall be pledged, hypothecated, or otherwise encumbered or subject to any lien, obligation, or liability of such Grantee to any party,
or assigned or transferred by such Grantee otherwise than by will or the laws of descent and distribution or to a Beneficiary upon the
death of a Grantee. Unless otherwise determined by the Committee in accordance with the provisions of the immediately preceding sentence,
an Award may be exercised during the lifetime of the Grantee only by the Grantee or, during the period the Grantee is under a Disability,
by the Grantee’s guardian or legal representative.

 

(b)
Notwithstanding Section 7.2.4(a), an Award other than an Incentive Stock Option may, in the Committee’s sole discretion, be transferable
by gift or domestic relations order to (i) the Grantee’s child, stepchild, grandchild, parent, stepparent, grandparent, spouse,
former spouse, sibling, niece, nephew, mother-in-law, father-in-law, daughter-in-law, son-in-law, brother-in-law, or sister-in-law, including
adoptive relationships (such persons, “Family Members”), (ii) a corporation, partnership, limited liability company, or other
business entity whose only stockholders, partners, or members, as applicable are the Grantee and/or Family Members, or (iii) a trust
in which the Grantee and/or Family Members have all of the beneficial interests, and subsequent to any such transfer any Award may be
exercised by any such transferee, provided, however, no Award may be transferred for value (as defined in the General Instructions to
Form S-8 Registration Statement).

 

(c)
Notwithstanding Sections 7.2.4(a) and 7.2.4(b), an Award may be transferred pursuant to a domestic relations order that would satisfy
Section 414(p)(1)(A) of the Code if such Section applied to an Award under this Plan, but only if the tax consequences flowing from the
assignment or transfer are specified in said order, the order is accompanied by signed agreement by both or all parties to the domestic
relations order, and, if requested by the Committee, an opinion is provided by qualified counsel for the Grantee that the order is enforceable
by or against this Plan under applicable law, and said opinion further specifies the tax consequences flowing from the order and the
appropriate tax reporting procedures for this Plan.

 

7.2.5
Notwithstanding any other provision of this Plan or agreements made pursuant thereto, the Company’s obligation to issue or deliver
any certificate or certificates for shares of Common Stock under a Stock Option or Stock Award, and the transferability of Common Stock
acquired by exercise of a Stock Option or grant of a Stock Award, shall be subject to all of the following conditions:

 

(a)
Any registration or other qualification of such shares under any state or federal law or regulation, or the maintaining in effect of
any such registration or other qualification that the Board shall, in its absolute discretion upon the advice of counsel, deem necessary
or advisable; and

 

(b)
The obtaining of any other consent, approval, or permit from any state or federal governmental agency that the Board shall, in its absolute
discretion upon the advice of counsel, determine to be necessary or advisable.

 

The
Company may, to the extent deemed necessary or advisable by the Committee, postpone the issuance or delivery of Common Stock or payment
of other benefits under any Award until completion of such registration or qualification of such Common Stock (including, but not limited
to, the conditions described in Sections 7.2.5(a) and 7.2.5(b) above) or other required action under any federal or state law, rule or
regulation, listing, or other required action with respect to any stock exchange or automated quotation system upon which the Shares
or other Company securities are listed or quoted, or compliance with any other obligation of the Company, as the Committee, may consider
appropriate, and may require any Grantee to make such representations, furnish such information and comply with or be subject to such
other conditions as it may consider appropriate in connection with the issuance or delivery of Shares or payment of other benefits in
compliance with applicable laws, rules, and regulations, listing requirements, or other obligations.

 

7.2.6
All payments to Grantees or to their legal representatives shall be subject to any applicable tax, community property, or other statutes
or regulations of the United States or of any state or country having jurisdiction over such payments. The Grantee may be required to
pay to the Company the amount of any withholding taxes that the Company is required to withhold with respect to a Stock Option or its
exercise or a Stock Award. In the event that such payment is not made when due, the Company shall have the right to deduct, to the extent
permitted by law, from any payment of any kind otherwise due to such person all or part of the amount required to be withheld.

 

    	 

    	 

    

 

7.2.7
In the case of a grant of a Stock Option or Stock Award to any Employee of a Subsidiary, the Company may, if the Committee so directs,
issue or transfer the shares, if any, covered by the Stock Option or Stock Award to such Subsidiary, for such lawful consideration as
the Committee may specify, upon the condition or understanding that such Subsidiary will transfer the shares to the Employee in accordance
with the terms of the Stock Option or Stock Award specified by the Committee pursuant to the provisions of this Plan.

 

7.2.8
A Grantee entitled to Common Stock as a result of the exercise of a Stock Option or grant of a Stock Award shall not be deemed for any
purpose to be, or have rights as, a stockholder of the Company by virtue of such exercise, except to the extent that a stock certificate
is issued therefor and then only from the date such certificate is issued. No adjustments shall be made for dividends or distributions
or other rights for which the record date is prior to the date such stock certificate is issued. The Company shall issue any stock certificates
required to be issued in connection with the exercise of a Stock Option with reasonable promptness after such exercise.

 

7.2.9
The grant or exercise of Stock Options granted under this Plan or the grant of a Stock Award under this Plan shall be subject to, and
shall in all respects comply with, applicable law relating to such grant or exercise, or to the number of shares of Common Stock that
may be beneficially owned or held by any Grantee.

 

7.2.10
The Company intends that this Plan shall comply with the requirements of Rule 16b-3 (the “Rule”) under the Securities Exchange
Act of 1934, as amended, during the term of this Plan. Should any additional provisions be necessary for this Plan to comply with the
requirements of the Rule, the Board may amend this Plan to add to or modify the provisions of this Plan accordingly.

 

7.2.11
Code Section 409A.

 

(a)
If any Award constitutes a “nonqualified deferred compensation plan” under Section 409A of the Code (a “Section 409A
Plan”), then the Award shall be subject to the following additional requirements, if and to the extent required to comply with
Section 409A of the Code:

 

(i)
Payments under the Section 409A Plan may not be made earlier than (u) the Grantee’s separation from service, (v) the date the Grantee
becomes disabled, (w) the Grantee’s death, (x) a specified time (or pursuant to a fixed schedule) specified in the Award Agreement
at the date of the deferral of such compensation, (y) a change in the ownership or effective control of the corporation, or in the ownership
of a substantial portion of the assets of the corporation, or (z) the occurrence of an unforeseeable emergency;

 

(ii)
The time or schedule for any payment of the deferred compensation may not be accelerated, except to the extent provided in applicable
Treasury Regulations or other applicable guidance issued by the Internal Revenue Service;

 

(iii)
Any elections with respect to the deferral of such compensation or the time and form of distribution of such deferred compensation shall
comply with the requirements of Section 409A(a)(4) of the Code; and

 

(iv)
In the case of any Grantee who is specified employee, a distribution on account of a separation from service may not be made before the
date that is six (6) months after the date of the Grantee’s separation from service (or, if earlier, the date of the Grantee’s
death).

 

    	 

    	 

    

 

For
purposes of the foregoing, the terms “separation from service”, “disabled,” and “specified employee”,
all shall be defined in the same manner as those terms are defined for purposes of Section 409A of the Code, and the limitations set
forth herein shall be applied in such manner (and only to the extent) as shall be necessary to comply with any requirements of Section
409A of the Code that are applicable to the Award.

 

(b)
The Award Agreement for any Award that the Committee reasonably determines to constitute a Section 409A Plan, and the provisions of this
Plan applicable to that Award, shall be construed in a manner consistent with the applicable requirements of Section 409A, and the Committee,
in its sole discretion and without the consent of any Grantee, may amend any Award Agreement (and the provisions of this Plan applicable
thereto) if and to the extent that the Committee determines that such amendment is necessary or appropriate to comply with the requirements
of Section 409A of the Code. No Section 409A Plan shall be adjusted, modified, or substituted for, pursuant to any provision of this
Plan, without the consent of the Grantee if any such adjustment, modification, or substitution would cause the Section 409A Plan to violate
the requirements of Section 409A of the Code.

 

(c)
The Company intends that this Plan shall comply with the requirements of Section 409A of the Code, to the extent applicable. Should any
changes to this Plan be necessary for this Plan to comply with the requirements of Section 409A, the Board may amend this Plan to add
to or modify the provisions of this Plan accordingly.

 

7.2.12
The validity, construction, and effect of this Plan, any rules and regulations under this Plan, and any Award Agreement shall be determined
in accordance with the laws of the State of Nevada without giving effect to principles of conflict of laws, and applicable federal law.
Unless otherwise provided in the Award Agreement, recipients of an Award under this Plan are deemed to submit to the exclusive jurisdiction
and venue of the federal or state courts whose jurisdiction covers California to resolve any and all issues that may arise out of or
relate to this Plan or any related Award Agreement.

 

7.2.13
The Board shall have the authority to adopt such modifications, procedures, and subplans as may be necessary or desirable to comply with
provisions of the laws of foreign countries in which the Company or its Related Entities may operate to assure the viability of the benefits
from Awards granted to Grantees performing services in such countries and to meet the objectives of this Plan.

 

7.2.14
The Company will seek stockholder approval in the manner and to the degree required under applicable laws. If the Company fails to obtain
any required stockholder approval of this Plan within twelve (12) months after the date this Plan is adopted by the Board, pursuant to
Section 422 of the Code, any Option granted as an Incentive Stock Option at any time under this Plan will not qualify as an Incentive
Stock Option within the meaning of the Code and will be deemed to be a Non-Statutory Stock Option.Exhibit
10.4

 

CONTRIBUTION
AGREEMENT

 

This
Contribution Agreement (the “Agreement”) is made effective as of the 18th day of August, 2015 (the
“Effective Date”) among Hand MD, LLC, a California limited liability company (“Seller”);
Kara Harshbarger, Alex Khadavi and Afshin Shargani (each a “Principal Owner”); Synergy CHC Corp., a Nevada
corporation (“Synergy”); and Hand MD Corp., a Delaware corporation (“Hand MD”). Hand
MD, Synergy, Principal Owners and Seller are sometimes referred to collectively as the “Parties” and individually
as a “Party”.

 

BACKGROUND

 

A.
Seller is engaged in the business of developing, manufacturing, and selling skincare, nail care and nail polish products (the “Products”)
(the Products and the business related to the Products is collectively the “Seller Business”).

 

B.
The Principal Owners, either directly or indirectly, collectively own all of the equity of Seller.

 

C.
Seller holds all right, title and interest in and to all Intellectual Property used in the Seller Business.

 

D.
Seller wishes to contribute the Intellectual Property, together with certain other assets, to Hand MD under the terms and conditions
set forth below in exchange for shares of the capital stock of Hand MD. Hand MD will be jointly owned by Synergy and Seller.

 

AGREEMENT

 

NOW,
THEREFORE, for and in consideration of the mutual promises, covenants, and agreements contained herein, and other good and valuable consideration,
the receipt and sufficiency of which are hereby acknowledged by the Parties, the Parties agree as follows:

 

1.
Definitions.

 

“Affiliate”
means, as to any Person, any other Person which directly or indirectly controls, or is under common control with, or is controlled by,
such Person. As used in this definition, “control” (including, with its correlative meanings, “controlled by”
and “under common control with”) shall mean possession, directly or indirectly, of the power to direct or cause the direction
of management or policies (whether through ownership of securities or partnership or other ownership interests, by contract or otherwise)
of such Person;

“

Assigned
Contracts” means all contracts, licenses, instruments, obligations, promises, undertaking, and equipment leases and other
agreements, whether written or oral, which are used in, support the production and sale of the Products or are related to the Seller
Business;

 

“Closing”
means the consummation of the transactions contemplated by this Agreement;

 

“Files
and Records” shall mean all files and records, whether in hard copy or digital, electronic, data, magnetic or other format,
of Seller relating to or used in connection with the Seller Business or otherwise relating to the Contributed Assets;

 

“Intellectual
Property” means all intellectual property rights whether protected, created or arising under the laws of the United States
or any other jurisdiction, including the following: (i) patents and patent applications; (ii) trademarks and service marks, including
all applications and registrations and goodwill related to the foregoing; (iii) copyrights, including all applications and registrations
related to the foregoing (including, without limitation, for all designs); (iv) Internet domain names; (v) telephone numbers, electronic
mail addresses and social media accounts and registrations, including but not limited to accounts and registrations with Facebook, LinkedIn,
Twitter, and other similar services; and (vi) trade secrets, know-how, ideas, creative works, inventions, discoveries, methods, processes,
technical data, specifications, research and development information, technology, software or computer programs, and data base.

 

    	 

    	 

    

 

“IP
Assets” has the meaning set forth in Section 5;

 

“Knowledge
of Seller” or “Seller’s Knowledge” or a similar phrase means, with respect to any matter,
the actual knowledge of the members, officers or managers of Seller or the Principal Owners, or facts regarding such matter which reasonably
should have been known by such persons after making a diligent inquiry with respect to such matter;

 

“Person”
means any individual, corporation, limited liability company, partnership, joint venture, association, joint-stock company, trust, any
other unincorporated organization or government;

 

“Transaction
Documents” means this Agreement, the Bill of Sale, the IP Assignment Agreement, and the other exhibits and schedules hereto
and thereto, and all other agreements, instruments, certificates and other documents to be entered into or delivered by any Party in
connection with the transactions contemplated to be consummated pursuant to any of the foregoing.

 

2.
Contribution of Assets. In exchange for the issuance of the Hand MD Securities (as defined below), Seller hereby grants, conveys,
assigns, transfers and delivers to Hand MD all rights, title and interest in and to all of its intellectual property assets, including,
without limitation, those specific assets set forth on Exhibit A attached hereto, and its Files and Records (collectively, the
“Contributed Assets”).

 

3.
Issuance of Hand MD Securities. In exchange for the contribution of the Contributed Assets and Seller’s execution of this
Agreement, Hand MD hereby agrees to issue to Seller 1,000,000 shares of its Common Stock (the “Hand MD Securities”),
representing fifty percent (50%) of Hand MD’s issued and outstanding capital stock on a fully-diluted basis as of the Closing.

 

4.
Hand MD Representations. Hand MD hereby represents and warrants to Seller as follows:

 

(a)
Corporate Organization. Hand MD is a corporation duly incorporated, validly existing and in good standing under the laws of the
State of Delaware, and has all requisite power and authority and all necessary governmental authority to own, operate or lease the properties
that it purports to own, operate or lease and to carry on its businesses as now conducted.

 

(b)
Authorization and Validity of Agreement. Hand MD has all requisite power and authority to enter into the Transaction Documents
and to carry out its obligations thereunder. The execution and delivery of the Transaction Documents and the performance of Hand MD’s
obligations thereunder have been duly authorized by all necessary company action by Hand MD, and no other proceedings on the part of
Hand MD are necessary to authorize such execution, delivery and performance. Each of the Transaction Documents has been duly executed
by Hand MD and constitutes its valid and binding obligation, enforceable against it in accordance with its terms.

 

(c)
No Conflict or Violation. The execution, delivery and performance by Hand MD of the Transaction Documents (i) does not and will
not violate or conflict with any provision of the organizational documents of Hand MD (ii) does not and will not violate any provision
of law, rule or regulation, or any order, judgment or decree of any court or other governmental or regulatory authority; (iii) does not
violate or will not result in a breach of or constitute (with due notice or lapse of time or both) a default under, or give rise to any
acceleration of remedies or any right of termination under, any contract, or other agreement or instrument to which Hand MD is a party.

 

5.
Seller Representations. Seller and each of the Principal Owners hereby jointly and severally represent and warrant as follows:

 

(a)
Organization. Seller is a limited liability company duly organized, validly existing and in good standing under the laws of its
jurisdiction of formation. The members of Seller do not, whether in their individual capacities or through any other entity, engage in
any other business that competes with the Seller Business.

 

(b)
Qualification to Do Business. Seller has the requisite power and authority and all necessary governmental authority to own, operate
or lease the Contributed Assets, and is in good standing in each jurisdiction where the character of its assets owned, operated or leased
or the nature of its activities makes such qualification necessary.

 

    	 

    	 

    

 

(c)
Authorization and Validity of Agreement. Seller and the Principal Owners each have all requisite power and authority to enter
into the Transaction Documents and to carry out their obligations thereunder. The execution and delivery of the Transaction Documents
and the performance of Seller’s and the Principal Owners’ obligations thereunder have been duly authorized by all necessary
corporate or member action of Seller, and no other proceedings on the part or in respect of Seller or the Principal Owners is necessary
to authorize such execution, delivery and performance. The Transaction Documents have been duly executed by Seller and the Principal
Owners and constitute valid and binding obligations, enforceable against Seller and the Principal Owners in accordance with their respective
terms.

 

(d)
No Conflict or Violation. The execution, delivery and performance by Seller and the Principal Owners of the Transaction Documents
does not and will not (a)(i) conflict with or result in a breach of the terms, conditions, or provisions of, (ii) constitute a default
under (whether with or without the passage of time, the giving of notice or both), (iii) give any third party the right to modify, terminate
or accelerate any obligation under, (iv) result in a violation of, or (v) require any consent, exemption or other action by or notice
or declaration to, or filing with, any third party of any government entity pursuant to (A) any organizational documents of Seller; (B)
any provision of law, rule or regulation, or any order, judgment or decree of any court or other governmental or regulatory authority;
(C) any contract, lease, sublease, occupancy agreement, loan agreement, mortgage, security agreement, trust indenture or other agreement
or instrument to which Seller is a party or by which Seller is bound or to which any of Seller’s properties or assets is subject;
or (D) the Assigned Contracts or other rights, agreements or licenses constituting the Contributed Assets; or (b) otherwise interfere
in any material manner with the operation of the Seller Business or the Contributed Assets or have any material adverse effect thereon.

 

(e)
QVC Statements. Attached hereto are financial statements regarding sale of the Products on QVC. The statements are complete and
correct and accurately reflect sales of the Products.

 

(f)
Absence of Undisclosed Liabilities; Indebtedness. Seller has no indebtedness or liability, absolute or contingent, involving,
affecting or relating to the Seller Business, the Contributed Assets, or the transactions contemplated by the Transaction Documents.

 

(g)
Intellectual Property.

 

	 	i.	“IP
    Assets” means all of the following materials owned or licensed by Seller with respect to the Seller Business: (A) all
    Intellectual Property used in the Seller Business, including, but not limited to, the proprietary formulas for the Products; (B)
    all domain names used by the Seller Business; (C) all the content on and accessible through the websites associated with such domain
    names; and (D) the entire Seller Business marketing database consisting of all available customer information and all marketing,
    advertising and promotional materials, including logos, colors, videos, booklet designs, catalogs, solicitations, email templates,
    advertisements and all other Seller Business marketing materials (whether in draft or final form).
	 	 	 
	 	ii.	Exhibit
    A lists all patented, registered, applied-for, and other Intellectual Property used in the Seller Business, and all Intellectual
    Property of Seller licensed to any third Person (collectively, the “Business Intellectual Property”), including
    the registration and application information, date of application or issuance and relevant jurisdiction as to each, and whether or
    not the Business Intellectual Property is owned or licensed. Business Intellectual Property that is licensed by Seller from a third
    party is “Licensed Intellectual Property”).

 

    	 

    	 

    

 

	 	iii.	Seller
    owns all right, title and interest in and to, or has a valid and enforceable license to use, all IP Assets, Business Intellectual
    Property, and the Licensed Intellectual Property, free and clear of all liens, and all patented or registered Business Intellectual
    Property is valid and enforceable. Seller has taken commercially reasonable steps to maintain the confidentiality of all information
    that constitutes a trade secret of the Seller Business. Seller has the valid right to transfer the Intellectual Property included
    in the Contributed Assets to Hand MD as contemplated hereunder.
	 	 	 
	 	iv.	(a)
    the conduct of the Seller Business, including the delivery and distribution of the Products has not infringed and does not infringe
    on any Intellectual Property or any other proprietary rights of any individual or entity, including but not limited to the rights
    of privacy or publicity; (b) no Person is infringing, violating or misappropriating any Business Intellectual Property; (c) Seller
    has not taken any action, or failed to take any action, during prosecution of any application that could reasonably be expected to
    result in the invalidation or unenforceability of any registered Business Intellectual Property; (d) Seller is not currently a party
    to any pending suit, claiming any alleged infringement or misappropriation of any Business Intellectual Property; (e) Seller has
    not received within the prior three (3) years any written notice, and is not currently a party to any pending suit, claiming any
    alleged infringement or misappropriation of the Intellectual Property rights of other Persons with respect to its or their use of
    Intellectual Property or the Products; (f) Seller has not entered into any contract that includes a forbearance to sue or settlement
    contract with respect to any Intellectual Property; and (g) Seller has not received any written notice of any claim within the prior
    three (3) years, and is not currently a party to any pending suit, which challenges the validity or enforceability of, Seller’s
    ownership of or right to use, any Intellectual Property (excluding, for clarity, office actions) or the Products. Seller has secured
    and has in place a policy to secure valid written confidentiality contracts and assignments of Intellectual Property from all consultants,
    contractors, employees and customers who contribute or have contributed to the creation, conception, reduction to practice or other
    development of any Intellectual Property developed on behalf of Seller.

 

(h)
Compliance with Law. The manufacture and sale of the Products, the operation of the Seller Business, and the business of Seller
has been conducted in material compliance with all applicable laws and other requirements of all courts and other governmental or regulatory
authorities having jurisdiction over the Seller and its assets, properties and operations. Seller has not received notice of any violation
(or possible violation) of any such law or other legal requirement, and the Seller is not in default with respect to any order, writ,
judgment, award, injunction or decree of any federal, state or local court or governmental or regulatory authority, applicable to Seller,
the Seller Business, or the Contributed Assets. Without limiting the foregoing, Seller has not received any warning letter or untitled
letter, report of inspectional observations, including FDA Form 483s, establishment inspection reports, notices of violation, clinical
holds, enforcement notices or other documents from the FDA or any other similar governmental entity or any institutional review board
or independent ethics committee alleging a lack of material compliance by Company with any laws. No “bulk sales” or similar
law applies to the transactions contemplated by this Agreement. Seller holds all permits required for the conduct of the Seller Business
and the ownership of its properties.

 

(i)
Litigation. There are no claims, actions, suits, proceedings, complaints or investigations pending or, to the Knowledge of the
Seller, threatened, before any federal, state, provincial or local court or governmental or regulatory authority, domestic or foreign,
or before any arbitrator of any nature, brought by or against the Seller or any of its members, managers, officers, directors, employees,
agents or Affiliates involving, affecting or relating to Seller, any member or manager of Seller, the Seller Business, the Contributed
Assets, or the transactions contemplated by the Transaction Documents.

 

    	 

    	 

    

 

(j)
Assigned Contracts. Each contract assigned to Hand MD is valid, binding and enforceable against the parties thereto in accordance
with its terms, and in full force and effect on the date hereof, except as may be limited by applicable bankruptcy, insolvency, moratorium
or similar laws of general application relating to or affecting creditors’ rights generally and except for the limitations imposed
by general principles of equity. Each Assigned Contract will remain in full force and effect without penalty in accordance with its terms
upon consummation of the Closing. Seller has performed all payment and other obligations required to be performed by it to date hereunder,
and is not in default or delinquent in performance, status or any other respect (claimed or actual) in connection with, any Assigned
Contract, and, to the Knowledge of the Seller, no event has occurred which, with due notice or lapse of time or both, would constitute
such a default. To the Knowledge of Seller, no other party to any Assigned Contract is in default in respect thereof, and, to the Knowledge
of Seller, no event has occurred which, with due notice or lapse of time or both, would constitute such a default. There is no breach
or cancellation or anticipated breach or cancellation by the other parties to any Assigned Contract.

 

(k)
Title to Contributed Assets. Seller has good and valid title to, or a valid leasehold interest in, the Contributed Assets, free
and clear of all liens.

 

(l)
Product and Service Warranties; Adverse Events. Seller has made no express warranty or guarantee to any customer as to services
or goods provided by Seller. There is no pending or, to the Knowledge of Seller, threatened claim alleging any breach of any warranty
or guarantee. There have not been any adverse events with respect to the Products of the Seller Business.

 

(m)
Clients and Vendors. Seller maintains commercially reasonable relations with each of its clients and vendors, and no event has
occurred that could materially and adversely affect Seller’s relations with any client or vendor.

 

(n)
Status. Seller and the Principal Owners each represent and warrant that (a) it has had an opportunity to discuss the business,
management and financial affairs of Hand MD, has had access to, the management of Hand MD, and has had the opportunity to review any
other information requested by Seller, and (b) Hand MD will be relying upon Seller’s and the Principal Owners’ representations
and warranties set forth herein in offering the Hand MD Securities to it. Seller and the Principal Owners further each represent and
warrant that: (i)(A) it has adequate net worth and means of providing for its current needs and possible contingencies to sustain a complete
loss in the Hand MD Securities, and has no need for liquidity of the Hand MD Securities; (B) it recognizes that ownership of the Hand
MD Securities involves substantial risks, including a risk of total loss of the value of the Hand MD Securities, and has taken full cognizance
of and understands all of the risk factors related to the ownership of the Hand MD Securities; and (C) it has sufficient knowledge and
experience in business and investments, including financial, business and tax matters, to be capable of evaluating the merits and risks
of ownership in Hand MD and making an informed decision about ownership in Hand MD; or (ii) is an “accredited investor” as
such term is defined in Rule 501 of Regulation D.

 

(o)
Acquisition for Own Account. This Agreement is made with Seller and the Principal Owners in reliance upon such parties’
representations Hand MD, which by its execution hereof Seller and the Principal Owners hereby confirm, that the Hand MD Securities to
be received by it will be acquired for investment for Seller’s own account, not as a nominee or agent, and not with a view to the
sale or distribution of any part thereof, and that it has no present intention of selling, granting participation in, or otherwise distributing
the same. By executing this Agreement, Seller further represents that it does not have any contract, undertaking, agreement, or arrangement
with any person to sell, transfer or grant participations to such person, or to any third person, with respect to the Hand MD Securities.

 

(p)
No Intention to Distribute. Seller and the Principal Owners understand that the Hand MD Securities have not been registered under
the Securities Act of 1933, as amended (the “1933 Act”) on the grounds that the sale provided for in
this Agreement and the issuance of securities hereunder is exempt from registration under the 1933 Act, and that Hand MD’s reliance
on such exemption is predicated in part on the representations set forth herein. Sellers and the Principal Owners realize that the basis
for the exemption may not be present if, notwithstanding such representations, Seller has in mind merely acquiring the Hand MD Securities
for a fixed or determined period in the future, or for a market rise, or for sale if the market does not rise. Seller and the Principal
Owners do not have any such intention.

 

    	 

    	 

    

 

(q)
No Registration. Seller and the Principal Owners understand that the Hand MD Securities may not be sold, transferred or otherwise
disposed of without registration under the 1933 Act or an exemption therefrom, and that in the absence of an effective registration statement
covering the Hand MD Securities or an available exemption from registration under the 1933 Act, the Hand MD Securities must be held indefinitely.
In particular, Seller and the Principal Owners are aware that the Hand MD Securities may not be sold pursuant to Rule 144 promulgated
under the 1933 Act unless all of the conditions of that Rule are met. Among the conditions for use of Rule 144 may be the availability
of current information to the public about Hand MD. Seller and the Principal Owners represent that, in the absence of an effective registration
statement covering the Hand MD Securities, it will sell, transfer, or otherwise dispose of such shares only in a manner consistent with
its representations set forth herein and the Bylaws of Hand MD, as the same may be amended from time to time.

 

(r)
Restrictions on Transfer. Seller agrees that in no event will it make a transfer or disposition of any of the Hand MD Securities
(other than pursuant to an effective registration statement under the 1933 Act, or Rule 144 sale in compliance with the terms of such
Rule or, to Hand MD’s reasonable satisfaction, pursuant to an exemption from the 1933 Act), unless and until (i) Seller shall have
notified Hand MD of the proposed disposition and shall have furnished Hand MD with a statement of the circumstances surrounding the disposition,
and (ii) if requested by Hand MD, at the expense of Seller or transferee, it shall have furnished to Hand MD an opinion of counsel, reasonably
satisfactory to Hand MD, to the effect that such transfer may be made without registration under the 1933 Act.

 

(s)
No representation or warranty by Seller or the Principal Owners contained in this Agreement, and no statement contained in the Disclosure
Schedules or any other document, certificate or other instrument delivered to or to be delivered by or on behalf of Seller or the Principal
Owners pursuant to this Agreement, contains or will contain any untrue statement of a material fact or omits or will omit to state any
material fact necessary, in light of the circumstances under which it was or will be made, in order to make the statements herein or
therein not misleading. Seller does not have Knowledge of any fact that has specific application to Seller (other than general economic
or industry conditions) and that may materially adversely affect the Contributed Assets, that has not been set forth in this Agreement
or the Disclosure Schedules.

 

6.
Execution and Delivery of Instruments. In addition to any other documents to be delivered under other provisions of this Agreement,
on the Effective Date the Parties will execute and deliver (a) the IP Assignment Agreement, in substantially the form attached hereto
as Exhibit B (the “IP Assignment Agreement”), and (b) a bill of sale substantially in the form attached
hereto as Exhibit C (the “Bill of Sale”). Following the Effective Date, Seller agrees to duly execute
and deliver or cause to be executed and delivered all instruments of sale, conveyance, transfer and assignment, and all notices, releases,
acquittances and other documents that may be necessary to more fully grant, convey, transfer and assign, and deliver to, and vest in,
Hand MD the Contributed Assets hereby granted, conveyed, transferred and assigned.

 

7.
Post-Closing Matters. Seller shall preserve and maintain its organizational existence and remain in good standing for a period
of at least twenty-four (24) months after the Effective Date. As soon as practicable after the Effective Date, Seller shall take all
action necessary to remove all Product and Seller names and logos and color schemes and any other Intellectual Property or IP Assets
from their respective signage at all locations, letterhead, stationary, advertising, websites and other marketing materials and other
content available for viewing by the public, and will change its name with the California Secretary of State and all other jurisdictions
in which Seller has made registrations to transact business, and any other registrations and/or name filings such that Seller’s
name does not include the words “Hand MD” or any derivative thereof, or any name which sounds or looks similar thereto, or
any trademarks or trade names used in the Seller Business, and Seller shall otherwise cease to use such names for all purposes, other
than as necessary for the winding up of its business affairs.

 

8.
Noncompetition, Nonsolicitation and Nondisparagement.

 

(a)
Noncompetition. Seller and the Principal Owners each acknowledge that (i) Hand MD and Synergy would not have entered into this
Agreement but for the agreements and covenants contained in this Section 8; and (ii) the agreements and covenants contained in
this Section 8 are reasonable and appropriate in scope; (iii) the Seller Business is worldwide in scope; and (iv) the business
of Hand MD is worldwide in scope. To induce Hand MD to enter into this Agreement, each of Seller and the Principal Owners covenants and
agrees that during the period commencing on the Effective Date and ending on the fifth (5th) anniversary of the Effective Date (the “Restricted
Period”), Seller, the Principal Owners and their respective Affiliates shall not, directly or indirectly, (A) engage in
any business or activity that competes with the Seller Business; (B) render any services to any Person for use in competing with Hand
MD in connection with the Seller Business; (C) have an interest in any Person engaged in any business that competes with Hand MD in connection
with the Seller Business, in any capacity, including, without limitation, as a shareholder, officer, director, principal, agent, trustee
or consultant or any other relationship or capacity; provided, however, Seller or any of the Principal Owners may own,
solely as an investment, securities of any Person which are publicly traded if Seller or such Principal Owner, as the case may be (I)
is not a controlling Person of, or a member of a group which controls, such Person and (II) does not own two percent (2%) or more of
any class of securities of such Person; or (D) interfere with business relationships (whether formed heretofore or hereafter) between
Hand MD or any of its Affiliates and customers, suppliers or prospects of the Seller Business. For purposes of this Section 8(a), with
respect only to Alex Khadavi, the “Seller Business” shall be defined as the business of developing, manufacturing,
and selling hand care, nail care and nail polish products.

 

    	 

    	 

    

 

(b)
Employees of the Business. During the Restricted Period, Seller, the Principal Owners and their respective Affiliates shall not,
directly or indirectly, (i) solicit or encourage any employee or consultant performing services in connection with the Seller Business
to leave the employment or retention of Hand MD or any of its Affiliates, or (ii) hire any such employee or consultant who was performing
services in connection with the Seller Business and who has left the employment or retention of Hand MD or any of its Affiliates within
one (1) year of the termination of such employee’s employment or consultant’s retention with Hand MD or any of its Affiliates.

 

(c)
Customers of the Business. During the Restricted Period, Seller, its employees, officers, directors, the Principal Owners, and
their respective Affiliates shall not (i) persuade or attempt to persuade any customer, prospective customer, client, prospective client,
supplier or vendor of Hand MD or any of its Affiliates not to hire or do business with Hand MD or any of its Affiliates or any successor
thereto; (ii) solicit for himself or any Person other than Hand MD or any of its Affiliates, the business of any Person who is a customer,
client, supplier or vendor of Hand MD or any of its Affiliates, or was its customer or supplier within two (2) years prior to the time
of such solicitation to the extent that such business is similar to the business conducted by such customer or supplier with Hand MD.

 

(d)
Confidential Information. From and after the Closing, Seller, its members, employees, officers, managers, the Principal Owners
and their respective Affiliates shall keep secret and retain in strictest confidence, and shall not use for the benefit of itself or
others, all confidential matters relating to the Seller Business or Hand MD and its Affiliates, including, but not limited to, “know
how”, trade secrets, customer lists, supplier lists, details of consultant and employment contracts, pricing policies, operational
methods, marketing plans or strategies, product development techniques or plans, business acquisition plans, technical processes, designs
and design projects, processes, inventions, software, source codes, object codes, systems documentation and research projects and other
business affairs (“Confidential Information”), and shall not disclose them to anyone outside of Hand MD and
its Affiliates; provided, however, this covenant shall not apply to any information which is or becomes generally available
to the public other than as a result of disclosure by the Seller, the Principal Owners or their respective Affiliates. Seller, the Principal
Owners and their respective Affiliates may disclose Confidential Information if required to do so in any legally required government
or securities filings, legal proceedings, subpoena, civil investigative demand or other similar process; provided, that Seller
(A) provides Hand MD with prompt notice of such required disclosure so that Hand MD may attempt to obtain a protective order, (B) cooperates
with Hand MD, at Hand MD’s expense, in obtaining such protective order, and (C) only discloses that Confidential Information which
it is absolutely required to disclose as advised by counsel.

 

(e)
Nondisparagement. After the Effective Date, Seller and the Principal Owners will not disparage Hand MD, any of Hand MD’s
Affiliates or any of such parties’ shareholders, directors, officers, employees or agents.

 

(f)
Tolling of Covenant Periods. The Restricted Period provided in this Section 8 shall not include and shall be extended beyond,
any time during which a party is failing to comply with any provision of this Section 8 with respect to such party.

 

(g)
Blue Penciling. If any term or other provision of this Section 8 is invalid, illegal, or incapable of being enforced by
any rule of law or public policy, all other conditions and provisions of this Section 8 shall nevertheless remain in full force
and effect. Upon determination that any term or other provision is invalid, illegal, or incapable of being enforced, the parties hereto
shall negotiate in good faith to, or the arbitrator making such a determination shall, modify this Section 8 so as to effect the
original intent of the parties as closely as possible in an acceptable manner to the end that the transactions contemplated hereby are
fulfilled to the extent possible.

 

    	 

    	 

    

 

9.
Indemnification.

 

(a)
Survival. All representations, warranties, covenants and agreements contained herein and all related rights to indemnification
shall survive the Closing.

 

(b)
Indemnification by Seller. Seller shall defend, indemnify and hold harmless Synergy, its affiliates and their respective stockholders,
directors, officers and employees from and against all claims, judgments, damages, liabilities, settlements, losses, costs and expenses,
including attorneys’ fees and disbursements, arising from or relating to:

 

	 	i.	any
    inaccuracy in or breach of any of the representations or warranties of Seller contained in this Agreement or any document to be delivered
    hereunder; or
	 	 	 
	 	ii.	any
    breach or non-fulfillment of any covenant, agreement or obligation to be performed by Seller pursuant to this Agreement or any document
    to be delivered hereunder.

 

(c)
Indemnification Procedures. Whenever any claim shall arise for indemnification hereunder, Synergy shall promptly provide written
notice of such claim to Seller. In connection with any claim giving rise to indemnity hereunder resulting from or arising out of any
action by a person or entity who is not a party to this Agreement, Seller, at its sole cost and expense and upon written notice to Synergy,
may assume the defense of any such action with counsel reasonably satisfactory to Synergy. Synergy shall be entitled to participate in
the defense of any such action, with its counsel and at its own cost and expense. If Seller does not assume the defense of any such action,
Synergy may, but shall not be obligated to, defend against such action in such manner as it may deem appropriate, including, but not
limited to, settling such action, after giving notice of it to Seller, on such terms as Synergy may deem appropriate and no action taken
by Synergy in accordance with such defense and settlement shall relieve Seller of its indemnification obligations herein provided with
respect to any damages resulting therefrom. Seller shall not settle any action without Synergy’s prior written consent (which consent
shall not be unreasonably withheld or delayed).

 

10.
Severability. In the event that any part of this Agreement is declared by any court or other judicial or administrative body to
be null, void or unenforceable, said provision shall survive to the extent it is not so declared, and all of the other provisions of
this Agreement shall remain in full force and effect.

 

11.
Governing Law; Jurisdiction. This Agreement shall be construed, performed and enforced in accordance with, and governed by, the
laws of the State of Delaware, without giving effect to the principles of conflicts of laws thereof. The Parties hereto irrevocably consent
to the exclusive jurisdiction of, the federal and state courts of the State of Delaware located in Wilmington, Delaware for such purpose.

 

12.
Notices. All notices, requests, demands and other communications under this Agreement shall be in writing and shall be deemed
to have been duly given (i) on the date of service if served personally on the Party to whom notice is to be given, or (ii) on the day
of delivery by Federal Express or similar overnight courier or the Express Mail service maintained by the U.S. Postal Service, to the
Party as follows:

 

	 	If
    to the Seller or any Principal Owner: 	Hand
    MD, LLC
	 	 	12121
    Wilshire Boulevard #1012
	 	 	Los
    Angeles, CA 90025
	 	 	Attention:
    Advanced Skin and Care
	 	 	 
	 	Copy
    to: 	Klehr
    Harrison Harvey Branzberg LLP
	 	 	1835
    Market Street, Suite 1400
	 	 	Philadelphia,
    PA 19103
	 	 	Attention:
    William W. Matthews, III
	 	 	 
	 	If
    to Hand MD:	Hand
    MD Corp.
	 	 	865
    Spring Street
	 	 	Westbrook,
    ME 04092
	 	 	Attention:
    President

 

	 	Copy
    to: 	Wyrick
    Robbins Yates & Ponton LLP
	 	 	4101
    Lake Boone Trail, Suite 300
	 	 	Raleigh,
    North Carolina 27607
	 	 	Attention:
    Zachary R. Bishop

 

    	 

    	 

    

 

Any
Party may change its address for the purpose of this Agreement by giving the other Party written notice of its new address in the manner
set forth above.

 

13.
Execution of Documents; Counterparts; Delivery by Facsimile or E-Mail. Each party agrees to execute all documents necessary to
carry out the purpose of this Agreement and to cooperate with each other for the expeditious filing of any and all documents and the
fulfillment of the terms of this Agreement. This Agreement may be executed in any number of counterparts with the same effect as if all
parties hereto had signed the same document. All counterparts shall be construed together and shall constitute one agreement. This Agreement
and any signed agreement or instrument entered into in connection with this Agreement or contemplated hereby, to the extent signed and
delivered by facsimile transmission or email (in PDF format), shall be treated in all manner and respects as an original agreement or
instrument and shall be considered to have the same binding legal effect as if it were the original signed version thereof delivered
in person.

 

14.
Successors and Assigns. Any Party hereto may assign this Agreement or any rights or obligations hereunder without the prior written
consent of the other Parties hereto; provided that this Agreement shall inure to the benefit of and shall be binding upon the successors
and assigns of the Parties hereto.

 

15.
Amendments; Waivers. This Agreement may be amended or modified, and any of the terms, covenants, representations, warranties or
conditions hereof may be waived, only by a written instrument executed by the Parties hereto, or in the case of a waiver, by the Party
waiving compliance. Any waiver by any Party of any condition, or of the breach of any provision, term, covenant, representation or warranty
contained in this Agreement, in any one or more instances, shall not be deemed to be nor construed as further or continuing waiver of
any such condition, or of the breach of any other provision, term, covenant, representation or warranty of this Agreement.

 

16.
Entire Agreement. This Agreement, the Exhibits and schedules hereto contain the entire understanding between the Parties hereto
with respect to the transactions contemplated hereby and thereby and supersede and replace all prior agreements and understandings, oral
or written, with regard to such transactions. All schedules and exhibits hereto and any documents and instruments delivered pursuant
to any provision hereof are expressly incorporated herein and made a part of this Agreement as fully as though completely set forth herein.
This Agreement shall only be binding on the Parties hereto upon execution and delivery of this Agreement by each of the Parties.

 

[THE
NEXT PAGE IS THE SIGNATURE PAGE]

 

    	 

    	 

    

 

IN
WITNESS WHEREOF, each of the undersigned parties has duly executed this Contribution Agreement, effective as of the date first set forth
above.

 

	 	HAND
    MD, LLC
	 	 	 
	 	By:
    	/s/
    Kara Harshbarger
	 	Name:	Kara
    Harshbarger
	 	Title:
    	President
	 	 	 
	 	HAND
    MD CORP.
	 	 	 
	 	By:
    	/s/
    Jack Ross
	 	Name:
    	Jack
    Ross
	 	Title:
    	President
	 	 	 
	 	SYNERGY
    CHC CORP.
	 	 	 
	 	By:
    	/s/
    Jack Ross 
	 	Name:
    	Jack
    Ross
	 	Title:
    	CEO
	 	 
	 	/s/
    Kara Harshbarger
	 	Kara
    Harshbarger
	 	 
	 	/s/
    Alex Khadavi
	 	Alex
    Khadavi
	 	 
	 	/s/
    Afshin Shargani
	 	Afshin
    Shargani

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00335-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00335-of-00352.parquet"}]]